Finanzen von IN8bio Inc (INAB)INABIN8bio Inc

Evaluating the bottom line, IN8bio Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -111.11%, provide a clear picture of how effectively INAB converts its operational activities into shareholder value.

In the context of the broader market, INAB competes directly with industry leaders such as TSBX and SNSE. With a market capitalization of $9.57M, it holds a leading position in the sector. When comparing efficiency, INAB's gross margin of N/A stands against TSBX's N/A and SNSE's N/A. Such benchmarking helps identify whether IN8bio Inc is trading at a premium or discount relative to its financial performance.

IN8BIO has shown a troubling trend of losses, with a net income of -$6.16 million in Q4 2024 and a negative EPS of -0.08. The company has a high current ratio of 10.50, indicating good liquidity, but its gross profit has been negative in several quarters, reflecting operational challenges.